In this interview, David Avigan, MD, from Beth Israel Deaconess Medical Centre, Boston, MA, discusses the exciting therapeutic area of personalized vaccines, which aim to produce tumor-specific immunity. Prof. Avigan discusses the settings that this has proven most successful in, and highlights promising pre-clinical and clinical trials. This video was recorded at the British Society for Haematology (BSH) 2018 Annual Scientific Meeting, in Liverpool, UK.
Personalized dendritic cell vaccine for acute leukemia and multiple myeloma
